计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E128064-5mg |
5mg |
现货 ![]() |
| |
| E128064-25mg |
25mg |
现货 ![]() |
| |
| E128064-100mg |
100mg |
现货 ![]() |
|
| 别名 | 依瓦塞特拉匹布 (LY2484595) |
|---|---|
| 英文别名 | Trans-4-(((5S)-5-(((3,5-bis(trifluoromethyl)phenyl)methyl)(2-methyl-2H-tetrazol-5- yl)amino)-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzazepin-1-yl)methyl) cyclohexanecarboxylic acid | Q553129 | 2-pyridine-carboxaldehyde | 4-trans-(((S)-5-((3,5-Bis(trifluorom |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Evacetrapib (LY2484595) |
| 生化机理 | Evacetrapib (LY2484595) 可抑制人血浆 CETP 蛋白,IC50 为 26 nM。Evacetrapib (LY2484595)(< 10 μM)不会诱导 H295R 细胞合成醛固酮或皮质醇。Evacetrapib (LY2484595)(30 mg/kg,口服)在人类载脂蛋白AI和CETP双转基因小鼠中,分别在服药后4小时、8小时和24小时抑制98.4%、98.6%和18.4%的CETP活性。口服 Evacetrapib(LY2484595)(30 毫克/千克)8 小时后,高密度脂蛋白胆固醇(HDL-C)增加了 129.7%。在两项剂量反应研究中,计算得出 Evacetrapib (LY2484595) 口服 8 小时后 CETP 抑制活性的 ED50 值分别为 3.5 mg/kg 和 4.1 mg/kg。Evacetrapib(LY2484595)(< 200 mg/kg)不会增加扎克糖尿病脂肪大鼠的血压。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 胆固醇酯转移蛋白抑制剂 |
| 产品介绍 |
Evacetrapib (LY2484595)是高活性CETP选择性抑制剂,IC50为5.5 nM,能在不增加醛固酮和血压的情况下提高高密度脂蛋白胆固醇。 Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. |
| 纯度 | ≥98% |
| ALogP | 7.7 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexane-1-carboxylic acid |
| INCHI | 1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20?,22?,26-/m0/s1 |
| InChi Key | IHIUGIVXARLYHP-UXNJHFGPSA-N |
| Smiles | CC1=CC(=C2C(=C1)C(CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C |
| Isomeric SMILES | CC1=CC(=C2C(=C1)[C@H](CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C |
| 分子量 | 638.65 |
| Reaxy-Rn | 38962088 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=38962088&ln= |
| 溶解性 | DMSO 12.8 mg/mL Water <1 mg/mL Ethanol 12.8 mg/mL |
|---|---|
| 分子量 | 638.600 g/mol |
| XLogP3 | 7.700 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 13 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 638.28 Da |
| 单同位素质量Monoisotopic Mass | 638.28 Da |
| 拓扑极表面积Topological Polar Surface Area | 87.400 Ų |
| 重原子数Heavy Atom Count | 45 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 973.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Fernandez MC, Escribano A, Mateo AI, Parthasarathy S, Martin de la Nava EM, Wang X, Cockerham SL, Beyer TP, Schmidt RJ, Cao G et al.. (2012) Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.. Bioorg Med Chem Lett, 22 (9): (3056-62). [PMID:22497761] |
| 2. Rader DJ, deGoma EM. (2014) Future of cholesteryl ester transfer protein inhibitors.. Annu Rev Med, 65 (385-403). [PMID:24422575] |
| 3. Sahebkar A, Chew GT, Watts GF. (2014) Recent advances in pharmacotherapy for hypertriglyceridemia.. Prog Lipid Res, 56 (47-66). [PMID:25083925] |
| 4. Ready JM. (2021) Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP).. J Med Chem, 64 (18): (13212-13214). [PMID:34498872] |